Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Dosing Comparison# Retatrutide Dosing# Based on Phase 2 trial data: Route : Once-weekly subcutaneous injection Dose range studied : 0.5 mg to 12 mg weekly Optimal dose : 12 mg weekly showed maximum efficacy in Phase 2 Titration : Gradual dose escalation over several weeks to manage GI tolerability Tirzepatide Dosing# Established FDA-approved dosing: Route : Once-weekly subcutaneous injection Starting dose : 2.5 mg weekly for 4 weeks Maintenance range : 5 mg, 10 mg, or 15 mg weekly Titration : 2.5 mg increments every 4 weeks to target dose Available formulations : Prefilled pens (Mounjaro/Zepbound) Tirzepatide's established titration protocol and prefilled pen delivery system offer practical advantages in clinical use
It is not approved for therapeutic use and is intended solely for laboratory and experimental applications
The disease prevalence ranges from 1 in 34,810 to as high as 1 in 8,664 live male births
Injectable forms are clearly regulated as compounded medications
While these lesions are always present at birth, the extent of the lesions may not be initially appreciated due to changes in size, shape, and pigmentation over time
US$ 29.24
US$ 28.44
US$ 20.55
US$ 22.69
US$ 20.60
US$ 27.87
US$ 27.96
US$ 25.92
US$ 21.65
US$ 22.47
US$ 20.86
US$ 27.62
US$ 21.95
